The synergistic effect of tautomycetin on cyclosporine a-mediated immunosuppression in a rodent islet allograft model

Molecular Medicine

Volumn 16, Issue 7-8, 2010, Pages 298-306

  Wee, Yu Mee ^a   Choi, Monica Young ^a   Kang, Choong Hoon ^a   Kim, Yang Hee ^a   Kim, Jin Hee ^a   Lee, Sang Kyou ^b   Yu, Seung Young ^c   Kim, Song Cheol ^a   Han, Duck Jong ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; INTERLEUKIN 10; INTERLEUKIN 2; MESSENGER RNA; TAUTOMYCETIN; TRANSCRIPTION FACTOR FOXP3; CYCLOSPORIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, RAT; FURAN DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MALE; MONOTHERAPY; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLEEN CELL; ALLOTRANSPLANTATION; ANIMAL; CELL SURVIVAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HISTOCOMPATIBILITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LEWIS RAT; LIVER; LYMPHOCYTE; METABOLISM; PANCREAS; PANCREAS ISLET; PROCEDURES; SPLEEN; SPRAGUE DAWLEY RAT;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CYCLOSPORINE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; FURANS; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; LIPIDS; LIVER; LYMPHOCYTES; MALE; PANCREAS; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; SPLEEN; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 77954294504     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2009.00099     Document Type: Article

References (24)

1. White SA, Nicholson ML, Hering BJ. (2000) Can islet cell transplantation treat diabetes? BMJ. 321:651-2.
2. Heit JJ. (2007) Calcineurin/NFAT signaling in the beta-cell: from diabetes to new therapeutics. Bioessays. 29:1011-21.
3. Nanji SA, Shapiro AM. (2004) Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs. 18:315-28.
4. Steiner JP, Dawson TM, Fotuhi M, Snyder SH. (1996) Immunophilin regulation of neurotransmitter release. Mol. Med. 2:325-33.
5. Helmchen U, Schmidt WE, Siegel EG, Creutzfeldt W. (1984) Morphological and functional changes of pancreatic B cells in cyclosporin A-treated rats. Diabetologia. 27:416-8.
6. Prokai A, et al. (2008) Post-transplant diabetes mellitus in children following renal transplantation. Pediatr. Transplant. 12:643-9.
7. Clipstone NA, Crabtree GR. (1992) Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357:695-7.
8. Ajabnoor MA, El-Naggar MM, Elayat AA, Abdulrafee A. (2007) Functional and morphological study of cultured pancreatic islets treated with cyclosporine. Life Sci. 80:345-55.
9. Shapiro AM, et al. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343:230-8.
10. Mitsuhashi S, et al. (2003) Usage of tautomycetin, a novel inhibitor of protein phosphatase 1 (PP1), reveals that PP1 is a positive regulator of Raf-1 in vivo. J Biol. Chem. 278:82-8.
11. Cohen PT. (2002) Protein phosphatase 1: targeted in many directions. J. Cell Sci. 115:241-56.
12. Mumby MC, Walter G. (1993) Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth. Physiol. Rev. 73:673-99.
13. Mitsuhashi S, et al. (2001) Tautomycetin is a novel and specific inhibitor of serine/threonine protein phosphatase type 1, PP1. Biochem. Biophys. Res. Commun. 287:328-31.
14. Han DJ, et al. (2003) Tautomycetin as a novel immunosuppressant in transplantation. Transplant Proc. 35:547.
15. Shim JH, et al. (2002) Immunosuppressive effects of tautomycetin in vivo and in vitro via T cell-specific apoptosis induction. Proc. Natl. Acad. Sci. U. S. A. 99:10617-22.
16. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. (2001) Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765.
17. Fontenot JD, Gavin MA, Rudensky AY. (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:330-6.
18. Allan SE, et al. (2008) CD4+ T-regulatory cells: toward therapy for human diseases. Immunol. Rev. 223:391-421.
19. Kim YH, et al. (2008) Viral IL-10 gene transfer prolongs rat islet allograft survival. Cell Transplant. 17:609-18.
20. Wee YM, et al. (2008) Cell surface modification by activated polyethylene glycol prevents allosensitization after islet transplantation. Cell Transplant. 17:1257-69.
21. Lee JH, et al. (2006) Tautomycetin inhibits growth of colorectal cancer cells through p21cip/WAF1 induction via the extracellular signal-regulated kinase pathway. Mol. Cancer Ther. 5:3222-31.
22. Kim JH, et al. (2005) Effects of tautomycetin on proliferation and fibronectin secretion in vascular smooth muscle cells and glomerular mesangial cells. Transplant Proc. 37:1959-61.
23. Heslan JM, et al. (2006) New evidence for a role of allograft accommodation in long-term tolerance. Transplantation. 82:1185-93.
24. Jiang S, Lechler RI, He XS, Huang JF. (2006) Regulatory T cells and transplantation tolerance. Hum. Immunol. 67:765-76.